The products are not intended to diagnose, treat, cure, or prevent any disease
In some embodiments, the pharmaceutical formulations or compositions described herein are stable with respect to compound degradation over a period of any of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, or at least about 6 months
Phase 2 clinical data shows a clean linear dose-response relationship, with each dose tier producing approximately 3 additional percentage points of weight loss
Reduction in Visceral Fat Tesamorelin has shown impressive reductions in abdominal visceral fat , particularly in HIV-related lipodystrophy but also in non-HIV populations
